Albaneze, N., Cotton, C. C., Anderson, C., Katzka, D. A., & Dellon, E. S. (2024). No Association Between Eosinophilic Oesophagitis and Oesophageal Cancer in US Adults: A Case–Control Study. Alimentary Pharmacology & Therapeutics, 61(2), 363–368. Portico. https://doi.org/10.1111/apt.18431

Zhang, Y., Karagiannis, D., Liu, H., Lin, M., Fang, Y., Jiang, M., Chen, X., Suresh, S., Huang, H., She, J., Shi, F., Liu, J., Luo, D., Angel, J. C., Lin, G., Yang, P., El-Rifai, W., Zaika, A., Oro, A. E., … Que, J. (2024). Epigenetic regulation of p63 blocks squamous-to-neuroendocrine transdifferentiation in esophageal development and malignancy. Science Advances, 10(41). https://doi.org/10.1126/sciadv.adq0479

Jukema, J. B., Kusters, C. H. J., Jong, M. R., Fockens, K. N., Boers, T., van der Putten, J. A., Pouw, R. E., Duits, L. C., Weusten, B. L. A. M., Herrero, L. A., Houben, M. H. M. G., Nagengast, W. B., Westerhof, J., Alkhalaf, A., Mallant-Hent, R., Scholten, P., Ragunath, K., Seewald, S., Elbe, P., … Wolfsen, H. C. (2024). Computer-aided diagnosis improves characterization of Barrett’s neoplasia by general endoscopists (with video). Gastrointestinal Endoscopy, 100(4), 616-625.e8. https://doi.org/10.1016/j.gie.2024.04.013

Su, S. H., Mitani, Y., Li, T., Sachdeva, U., Flashner, S., Klein-Szanto, A., Dunbar, K. J., Abrams, J., Nakagawa, H., & Gabre, J. (2024). Lactate Suppresses Growth of Esophageal Adenocarcinoma Patient-Derived Organoids through Alterations in Tumor NADH/NAD+ Redox State. Biomolecules, 14(9), 1195. https://doi.org/10.3390/biom14091195

Henick, B. S., & Moy, R. H. (2024). TAPping Into PD-L1 Testing Efficiency for Gastroesophageal Cancer. JCO Precision Oncology, 8. https://doi.org/10.1200/po.24.00344

Rustgi, N., Wu, S., Samec, T., Walker, P., Xiu, J., Lou, E., Goel, S., Saeed, A., & Moy, R. H. (2024). Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer. Cancer Research Communications, 4(6), 1399–1409. https://doi.org/10.1158/2767-9764.crc-23-0496

Ng, A. W. T., McClurg, D. P., Wesley, B., Zamani, S. A., Black, E., Miremadi, A., Giger, O., Hoopen, R. ten, Devonshire, G., Redmond, A. M., Grehan, N., Jammula, S., Blasko, A., Li, X., Aparicio, S., Tavaré, S., Edwards, P. A. W., Grehan, N., … Fitzgerald, R. C. (2024). Disentangling oncogenic amplicons in esophageal adenocarcinoma. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47619-4

Solfisburg, Q. S., Baldini, F., Baldwin-Hunter, B., Austin, G. I., Lee, H. H., Park, H., Freedberg, D. E., Lightdale, C. J., Korem, T., & Abrams, J. A. (2023). The Salivary Microbiome and Predicted Metabolite Production Are Associated with Barrett’s Esophagus and High-Grade Dysplasia or Adenocarcinoma. Cancer Epidemiology, Biomarkers & Prevention, 33(3), 371–380. https://doi.org/10.1158/1055-9965.epi-23-0652

Weh, K. M., Howard, C. L., Zhang, Y., Tripp, B. A., Clarke, J. L., Howell, A. B., Rubenstein, J. H., Abrams, J. A., Westerhoff, M., & Kresty, L. A. (2024). Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome. JCI Insight. https://doi.org/10.1172/jci.insight.168112

Sun, J., Sepulveda, J. L., Komissarova, E. V., Hills, C., Seckar, T. D., LeFevre, N. M., Simonyan, H., Young, C., Su, G., Del Portillo, A., Wang, T. C., & Sepulveda, A. R. (2024). CDKN2A-p16 Deletion and Activated KRASG12D Drive Barrett’s-Like Gland Hyperplasia-Metaplasia and Synergize in the Development of Dysplasia Precancer Lesions. Cellular and Molecular Gastroenterology and Hepatology, 17(5), 769–784. https://doi.org/10.1016/j.jcmgh.2024.01.014

Yoon, J. Y., Lim, F., Shah, S. C., Rubenstein, J. H., Abrams, J. A., Katzka, D., Inadomi, J., Kim, M. K., & Hur, C. (2024). Endoscopic Surveillance of Intestinal Metaplasia of the Esophagogastric Junction: A Decision Modeling Analysis. American Journal of Gastroenterology, 119(7), 1289–1297. https://doi.org/10.14309/ajg.0000000000002672

Dunbar, K. J., Wong, K. K., & Rustgi, A. K. (2024). Cancer-Associated Fibroblasts in Esophageal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 17(5), 687–695. https://doi.org/10.1016/j.jcmgh.2024.01.008

Flashner, S., Shimonosono, M., Tomita, Y., Matsuura, N., Ohashi, S., Muto, M., Klein-Szanto, A. J., Alan Diehl, J., Chen, C.-H., Mochly-Rosen, D., Weinberg, K. I., & Nakagawa, H. (2023). ALDH2 dysfunction and alcohol cooperate in cancer stem cell enrichment. Carcinogenesis, 45(1–2), 95–106. https://doi.org/10.1093/carcin/bgad085

Efe, G., Dunbar, K. J., Sugiura, K., Cunningham, K., Carcamo, S., Karaiskos, S., Tang, Q., Cruz-Acuña, R., Resnick-Silverman, L., Peura, J., Lu, C., Hasson, D., Klein-Szanto, A. J., Taylor, A. M., Manfredi, J. J., Prives, C., & Rustgi, A. K. (2023). p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression. Cancer Discovery, 13(12), 2632–2651. https://doi.org/10.1158/2159-8290.cd-23-0601

Manji, G. A., Lee, S., Del Portillo, A., May, M., Ana, S. S., Alouani, E., Sender, N., Negri, T., Gautier, K., Ge, L., Fan, W., Xie, M., Sethi, A., Schrope, B., Tan, A. C., Park, H., Oberstein, P. E., Shah, M. A., & Raufi, A. G. (2023). Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma. JAMA Oncology, 9(12), 1702. https://doi.org/10.1001/jamaoncol.2023.4423

Muthupalani, S., Annamalai, D., Feng, Y., Ganesan, S. M., Ge, Z., Whary, M. T., Nakagawa, H., Rustgi, A. K., Wang, T. C., & Fox, J. G. (2023). IL-1β transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-39907-8

Cruz-Acuña, R., Kariuki, S. W., Sugiura, K., Karaiskos, S., Plaster, E. M., Loebel, C., Efe, G., Karakasheva, T., Gabre, J. T., Hu, J., Burdick, J. A., & Rustgi, A. K. (2023). Engineered hydrogel reveals contribution of matrix mechanics to esophageal adenocarcinoma and identifies matrix-activated therapeutic targets. Journal of Clinical Investigation, 133(23). https://doi.org/10.1172/jci168146

Chandar, A. K., Keerthy, K., Gupta, R., Grady, W. M., Canto, M. I., Shaheen, N. J., Thota, P. N., Iyer, P. G., Wang, J. S., Falk, G. W., Abrams, J. A., Dumot, J., Faulx, A., Markowitz, S. D., Willis, J., Moinova, H., Guda, K., Brock, W., & Chak, A. (2023). Patients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Sectional Study. American Journal of Gastroenterology, 119(5), 823–829. https://doi.org/10.14309/ajg.0000000000002593

Crowe, B. R., Krigel, A., Li, T., Haile, R., Al-Ani, F., Lebwohl, B., Abrams, J. A., & Araujo, J. L. (2023). Veterans with multiple risk factors for Barrett’s esophagus are infrequently evaluated with upper endoscopy. Diseases of the Esophagus, 36(9). https://doi.org/10.1093/dote/doad007

Cytryn, S. L., Moy, R. H., Cowzer, D., Shah, R. H., Chou, J. F., Joshi, S. S., Ku, G. Y., Maron, S. B., Desai, A., Yang, J., Sugarman, R., Rao, D., Goldberg, Z., Charalambous, C., Lapshina, M., Antoine, A., Socolow, F., Trivedi, N., Capanu, M., … Janjigian, Y. Y. (2023). First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. The Lancet Oncology, 24(10), 1073–1082. https://doi.org/10.1016/s1470-2045(23)00358-3

Ko, K.-P., Huang, Y., Zhang, S., Zou, G., Kim, B., Zhang, J., Jun, S., Martin, C., Dunbar, K. J., Efe, G., Rustgi, A. K., Nakagawa, H., & Park, J.-I. (2023). Key Genetic Determinants Driving Esophageal Squamous Cell Carcinoma Initiation and Immune Evasion. Gastroenterology, 165(3), 613-628.e20. https://doi.org/10.1053/j.gastro.2023.05.030

Dunbar, K. J., Karakasheva, T. A., Tang, Q., Efe, G., Lin, E. W., Harris, M., Sahu, V., Sachdeva, U. M., Hu, J., Klein-Szanto, A. J., Henick, B., Diehl, J. A., Nakagawa, H., & Rustgi, A. K. (2023). Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma. Molecular Cancer Research, 21(7), 741–752. https://doi.org/10.1158/1541-7786.mcr-22-0872

Rubenstein, J. H., Burns, J. A., Arasim, M. E., Firsht, E. M., Harbrecht, M., Widerquist, M., Evans, R. R., Inadomi, J. M., Chang, J. W., Hazelton, W. D., Hur, C., Kurlander, J. E., Lim, F., Luebeck, G., Macdonald, P. W., Reddy, C. A., Saini, S. D., Tan, S. X., Waljee, A. K., & Lansdorp-Vogelaar, I. (2023). Yield of Repeat Endoscopy for Barrett’s Esophagus After Normal Index Endoscopy. American Journal of Gastroenterology, 118(7), 1168–1174. https://doi.org/10.14309/ajg.0000000000002204

Shah, M. A., Altorki, N., Patel, P., Harrison, S., Bass, A., & Abrams, J. A. (2023). Improving outcomes in patients with oesophageal cancer. Nature Reviews Clinical Oncology, 20(6), 390–407. https://doi.org/10.1038/s41571-023-00757-y

Quante, M., Wang, T. C., & Bass, A. J. (2022). Adenocarcinoma of the oesophagus: is it gastric cancer? Gut, 72(6), 1027–1029. https://doi.org/10.1136/gutjnl-2022-327096

Soroush, A., Malekzadeh, R., Roshandel, G., Khoshnia, M., Poustchi, H., Kamangar, F., Brennan, P., Boffetta, P., Dawsey, S. M., Abnet, C. C., Abrams, J. A., & Etemadi, A. (2022). Sex and smoking differences in the association between gastroesophageal reflux and risk of esophageal squamous cell carcinoma in a high‐incidence area: Golestan Cohort Study. International Journal of Cancer, 152(6), 1137–1149. Portico. https://doi.org/10.1002/ijc.34313

Chen, L., Lu, H., Peng, D., Cao, L. L., Ballout, F., Srirmajayam, K., Chen, Z., Bhat, A., Wang, T. C., Capobianco, A., Que, J., McDonald, O. G., Zaika, A., Zhang, S., & El-Rifai, W. (2022). Activation of NOTCH signaling via DLL1 is mediated by APE1-redox-dependent NF-κB activation in oesophageal adenocarcinoma. Gut, 72(3), 421–432. https://doi.org/10.1136/gutjnl-2022-327076

Flashner, S., Martin, C., Matsuura, N., Shimonosono, M., Tomita, Y., Morimoto, M., Okolo, O., Yu, V. X., Parikh, A. S., Klein-Szanto, A. J. P., Yan, K., Gabre, J. T., Lu, C., Momen-Heravi, F., Rustgi, A. K., & Nakagawa, H. (2022). Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids. Journal of Visualized Experiments, 190. https://doi.org/10.3791/64676

Kabir, M. F., Karami, A. L., Cruz-Acuña, R., Klochkova, A., Saxena, R., Mu, A., Murray, M. G., Cruz, J., Fuller, A. D., Clevenger, M. H., Chitrala, K. N., Tan, Y., Keith, K., Madzo, J., Huang, H., Jelinek, J., Karakasheva, T., Hamilton, K. E., Muir, A. B., … Whelan, K. A. (2022). Single cell transcriptomic analysis reveals cellular diversity of murine esophageal epithelium. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-29747-x

Ballout, F., Lu, H., Chen, L., Sriramajayam, K., Que, J., Meng, Z., Wang, T. C., Giordano, S., Zaika, A., McDonald, O., Peng, D., & El-Rifai, W. (2022). APE1 redox function is required for activation of Yes-associated protein 1 under reflux conditions in Barrett’s-associated esophageal adenocarcinomas. Journal of Experimental & Clinical Cancer Research, 41(1). https://doi.org/10.1186/s13046-022-02472-5

Dobashi, A., Li, D. K., Mavrogenis, G., Visrodia, K. H., & Bazerbachi, F. (2022). Endoscopic Management of Esophageal Cancer. Thoracic Surgery Clinics, 32(4), 479–495. https://doi.org/10.1016/j.thorsurg.2022.07.005

Wang, Z., Wang, J., Zhao, H., Zhao, T., Chen, Y., Jiang, M., Zhang, S., Wei, Y., Zhang, J., Zhou, Y., Shi, S., Fu, Z., Yang, Y., Zhang, Y., Yang, L., Que, J., & Liu, K. (2022). Targeting the SOX2/PARP1 complex to intervene in the growth of esophageal squamous cell carcinoma. Biomedicine & Pharmacotherapy, 153, 113309. https://doi.org/10.1016/j.biopha.2022.113309

Rubenstein, J. H., Omidvari, A.-H., Lauren, B. N., Hazelton, W. D., Lim, F., Tan, S. X., Kong, C. Y., Lee, M., Ali, A., Hur, C., Inadomi, J. M., Luebeck, G., & Lansdorp-Vogelaar, I. (2022). Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 163(1), 163–173. https://doi.org/10.1053/j.gastro.2022.03.037

Genere, J. R., Visrodia, K., Zakko, L., Hoefnagel, S. J. M., & Wang, K. K. (2022). Spray cryotherapy versus continued radiofrequency ablation in persistent Barrett’s esophagus. Diseases of the Esophagus, 35(5). https://doi.org/10.1093/dote/doab084

Ekheden, I., Ludvigsson, J. F., Yin, L., Elbe, P., & Ye, W. (2022). Esophageal abnormalities and the risk for gastroesophageal cancers—a histopathology-register-based study in Sweden. European Journal of Epidemiology, 37(4), 401–411. https://doi.org/10.1007/s10654-021-00833-6

Sahm, V., Maurer, C., Baumeister, T., Anand, A., Strangmann, J., Schmid, R. M., Wang, T. C., & Quante, M. (2022). Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker. Oncotarget, 13(1), 347–359. https://doi.org/10.18632/oncotarget.28198

Moy, R. H., Walch, H. S., Mattar, M., Chatila, W. K., Molena, D., Strong, V. E., Tang, L. H., Maron, S. B., Coit, D. G., Jones, D. R., Hechtman, J. F., Solit, D. B., Schultz, N., de Stanchina, E., & Janjigian, Y. Y. (2022). Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00242

Moy, R. H., Greally, M., Chou, J. F., Li, J., Desai, A. M., Chalasani, S. B., Won, E., Kelsen, D. P., Ilson, D. H., Janjigian, Y. Y., Capanu, M., & Ku, G. Y. (2022). Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 89(2), 255–265. https://doi.org/10.1007/s00280-021-04384-1

Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., Kachnic, L. A., Seaward, S., Mamon, H., Diaz Pardo, D. A., Anderson, C. M., Shen, X., Sharma, A. K., Katz, A. W., Salo, J., … Crane, C. H. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet Oncology, 23(2), 259–269. https://doi.org/10.1016/s1470-2045(21)00718-x